Related Experiment Video
Updated: Feb 8, 2026

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
Published on: October 27, 2014
Treatment of multiresistant prolactinomas with a combination of cabergoline and octreotide LAR
Ernesto Sosa-Eroza1, Etual Espinosa1, Claudia Ramírez-Rentería1
1Endocrinology Service and the Experimental Endocrinology Unit, Hospital de Especialidades, Centro Médico Nacional Siglo XXI, Instituto Mexicano del Seguro Social, Mexico City, MX, USA.
Background And Objectives:
Dopamine agonist (DA)-resistant prolactinomas are rare but they constitute a real challenge, since there are few therapeutic alternatives left for these patients.
Design And Setting:
Proof-of-concept study at a tertiary care, referral center.
Patients And Methods:
The studied population consisted of five patients (one female and four males, mean age at diagnosis 23.5 ± 19) with macroprolactinomas with persistent hyperprolactinemia and/or tumor mass despite high doses of cabergoline (CBG) and pituitary surgery, to whom 20 mg monthly of octreotide LAR was added for 6-13 months. Response was evaluated by measuring prolactin (PRL) levels and by magnetic resonance imaging. Immunohistochemistry (IHC) for pituitary hormones, Ki-67, and somatostatin receptor subtypes 2 and 5 was (SSTR2 and 5) was available in two of the subjects.
Results:
The addition of octreotide LAR to ongoing CBG treatment had no effect on either PRL levels or tumor size in three patients. In two of the five patients, combination treatment resulted in a significant reduction in PRL concentrations (from 7643 to 200 ng/mL and from 2587 to 470 ng/mL) as well as in adenoma size (93% reduction). IHC evaluation of tumor samples from two patients (a responder and a non-responder) revealed positive immunostaining for PRL and SSTR5 but not for other pituitary hormones or for SSTR2.
Conclusions:
The addition of a somatostatin analog to ongoing CBG treatment may be effective in some patients with DA-resistant macroprolactinomas, independently of the adenoma's SSTR expression profile.
Insights
Dopamine agonist-resistant prolactinomas are challenging. Adding octreotide LAR to cabergoline showed significant prolactin reduction and tumor shrinkage in some patients, offering a new treatment option.
Area of Science:
- Endocrinology
- Oncology
- Pharmacology
Background:
- Dopamine agonist (DA)-resistant prolactinomas present a significant therapeutic challenge due to limited treatment alternatives.
- Macroprolactinomas, particularly those resistant to DA therapy, require novel management strategies.
Purpose of the Study:
- To evaluate the efficacy of adding octreotide long-acting repeatable (LAR) to cabergoline (CBG) treatment in patients with DA-resistant macroprolactinomas.
- To assess the impact on prolactin (PRL) levels and tumor size.
Main Methods:
- A proof-of-concept study involving five patients with macroprolactinomas resistant to high-dose cabergoline and prior surgery.
- Patients received 20 mg monthly octreotide LAR in addition to ongoing cabergoline for 6-13 months.
- Response was assessed via prolactin levels, MRI, and immunohistochemistry (IHC) for somatostatin receptor subtypes (SSTR2 and SSTR5) in two cases.
Main Results:
- Three out of five patients showed no significant change in PRL levels or tumor size with the combination therapy.
- Two patients experienced substantial reductions in both PRL concentrations (e.g., from 7643 to 200 ng/mL) and adenoma size (up to 93% reduction).
- IHC analysis in responders and non-responders revealed positive SSTR5 staining, irrespective of SSTR2 expression.
Conclusions:
- The addition of a somatostatin analog may be a viable therapeutic option for select patients with dopamine agonist-resistant macroprolactinomas.
- Treatment efficacy appears independent of the adenoma's somatostatin receptor expression profile (SSTR2/SSTR5).
More Related Videos
Related Concept Videos
Impedance Combination
Combination Of Resistors
Combining Functions
Open Angle Glaucoma: Treatment
Drugs such as carbonic anhydrase inhibitors, α2- and...
Treatment Resistant Cancers
Stresses under Combined Loadings
The process begins by slicing the tube at critical points and analyzing the internal forces and stress components at these sections, focusing on the centroid. Normal stresses, generated by axial forces and bending moments, are either compressive or tensile and vary across the section from...

